Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide

Purpose: We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients. Methods: Biochemical data of patients rece...

Full description

Bibliographic Details
Main Authors:	Mitsutoshi Satoh, Rieko Oguro, Chigusa Yamanaka, Katsutoshi Takada, Yasuhiro Matsuura, Toyomi Akiba, Nobuyuki Aotsuka, Yoshihiro Tani, Hisashi Wakita
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2011-02-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8892

Similar Items

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-01-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-05-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
by: Jeng-Shiun Du, et al.
Published: (2022-01-01)

No influence of the polymorphisms <it>CYP2C19 </it>and <it>CYP2D6 </it>on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
by: Vogel Ulla, et al.
Published: (2010-08-01)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
by: Chim Chor
Published: (2010-11-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
by: V. Del Fabro, et al.
Published: (2023-05-01)

A feline case of multiple myeloma treated with bortezomib
by: Hiroyuki Tani, et al.
Published: (2022-11-01)

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis
by: Piechotta, V, et al.
Published: (2019)

Thalidomide and its analogues in the treatment of Multiple Myeloma
by: Latif Tahir, et al.
Published: (2012-09-01)

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
by: Veronika Kodre, et al.
Published: (2008-04-01)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
by: Karthik Ramasamy, et al.
Published: (2022-11-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib for the treatment of multiple myeloma patients
by: C Green, et al.
Published: (2009-06-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Association of Chromosome 17 Aneuploidy, <i>TP53</i> Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment
by: Sylwia Popek-Marciniec, et al.
Published: (2023-09-01)

The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
by: Sylwia Popek-Marciniec, et al.
Published: (2023-03-01)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
by: Priscilla Cury de Camargo Cury, et al.
Published: (2020-04-01)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
by: Antonio Villa, et al.
Published: (2011-09-01)

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
by: J Picot, et al.
Published: (2011-12-01)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01)

Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma
by: A Anagnostara, et al.
Published: (2001-03-01)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023-07-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma
by: Zohra El Ati, et al.
Published: (2019-01-01)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
by: Pieter Sonneveld, et al.
Published: (2020-11-01)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023-11-01)

Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma
by: Aleksandra Paterek, et al.
Published: (2023-04-01)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
by: Nicholas Nikesitch, et al.
Published: (2021-12-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)